Edgewise Therapeutics

EWTX Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$33.33

+0.57% today

52W: $10.60 – $33.55

52W Low: $10.60 Position: 99% 52W High: $33.55

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$3.6B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-34.19%

Return on Equity

Beta

0.25

Market sensitivity

Short Interest

10.34%

% of float sold short

Avg. Volume

975,018

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

12 analysts

Avg. Price Target

$41.08

+23.26% upside

Target Range

$20.00 – $51.00

About the Company

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address ge

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 146 Exchange: NMS